Mirdametinib for advanced NF1-mutant melanoma
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Skin clinical trials.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a clear NF1 gene change (mutation) in your melanoma, not a 'variant of unknown significance.'
- You should have already had at least one type of immunotherapy (like anti-PD-1/PD-L1, anti-CTLA-4, or anti-LAG3), unless your doctor says these treatments are not safe or suitable for you.
- Your melanoma must be growing or getting worse at the time you join the study.
- You cannot have had a MEK, ERK, or RAF inhibitor drug (like trametinib or vemurafenib) before.
- You must have adequate organ function (kidney, liver, blood counts, and heart) and no major eye problems or severe heart disease.
- If you have brain metastases, they must be small (under 6 mm), not require steroid treatment, and not cause symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This trial tests a drug called mirdametinib, which targets a protein linked to tumor growth, given alone or with radiation. It is for people with certain brain or spinal cord tumors, especially those with a condition called NF1, to see if it can help control the cancer.
This trial tests a study drug called mirdametinib in infants and toddlers who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas (non-cancerous nerve tumors). The study aims to see if the drug can shrink or control these tumors, which may help prevent or reduce symptoms.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
This program provides access to an investigational drug called mirdametinib for people with serious, debilitating, or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer a potential treatment when nothing else has worked.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.